Skip to main content
. 2018 Jun 7;11(2):95–104. doi: 10.3727/000000003108748991

Figure 5.

Figure 5

The 32-bp terminal sequence of the OPN first intron contains a C/EBP-beta binding site. (A) Gel retardation assay with a double-stranded oligonucleotide that reproduces the last 30-bp sequence of the first intron and nuclear extract from U2OS cells, in the absence (lane 4) or in the presence of wild-type competitor oligonucleotide at 50-, 100-, or 250-fold molar excess (lanes 1–3) or mutant competitor (lanes 5–7). The asterisk indicates sequence-specific retarded complexes; ns indicates nonspecific bands. (B) Gel retardation assay with same oligonucleotide and nuclear extract as in (A), in the absence of competitor and antibody (lane 3), in the presence of competitor oligonucleo-tide (lanes 1, 2, and 5), with anti-C/EBP-beta antibody (lane 4), with anti-GATA1 antibody (lane 6). The double asterisk indicates a supershifted complex.